April 2025
1. WITJES VM, de Hullu JA, Hermkens DMA, Smolders YHCM, et al
   Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.
   Int J Cancer. 2025 Apr 16. doi: 10.1002/ijc.35440.
   

   >> Share

   
   March 2025
2. WEI W, Zhang Y, Li Y, Huang J, et al
   Hypoxia-mediated high expression of TRIM15 promotes malignant progression of high-grade serous ovarian cancer through activation of AKT signaling pathway by K63 ubiquitination.
   Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35387.
   

   >> Share

   
   January 2025
3. LOFLING LL, Stoer NC, Sloan EK, Nafisi S, et al
   Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study.
   Int J Cancer. 2025 Jan 26. doi: 10.1002/ijc.35348.
   

   >> Share

   
   
4. LUND E, Busund LR, Holden L
   Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
   Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
   

   >> Share

   
   December 2024
5. VERROU E, Koutoukoglou P, Kontana E, Gogolopoulos S, et al
   Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.
   Int J Cancer. 2024 Dec 17. doi: 10.1002/ijc.35299.
   

   >> Share

   
   
6. HUNG FH, Peng HP, Hung CF, Hsieh LL, et al
   Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan.
   Int J Cancer. 2024;155:2201-2210.
   

   >> Share

   
   November 2024
7. JENSEN A, Guleria S, Albieri V, Nohr B, et al
   Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women.
   Int J Cancer. 2024 Nov 14. doi: 10.1002/ijc.35251.
   

   >> Share

   
   October 2024
8. BIGNOTTI E, Simeon V, Ardighieri L, Kuhn E, et al
   TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
   Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35203.
   

   >> Share

   
   September 2024
9. JONSSON S, Jonsson H, Lundin E, Haggstrom C, et al
   Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population-based case-control study in Sweden.
   Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35180.
   

   >> Share

   
   
10. NA R, Jordan SJ, DeFazio A, Williams M, et al
    Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in Australia.
    Int J Cancer. 2024 Sep 2. doi: 10.1002/ijc.35154.
    

    >> Share

    
    August 2024
11. VLEDDER A, Paijens ST, Loiero D, Maagdenberg A, et al
    B cells critical for outcome in high grade serous ovarian carcinoma.
    Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35149.
    

    >> Share

    
    July 2024
12. 
    Expression of Concern: miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
    Int J Cancer. 2024 Jul 31. doi: 10.1002/ijc.35121.
    

    >> Share

    
    
13. MORO F, Ciancia M, Zace D, Vagni M, et al
    Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review.
    Int J Cancer. 2024 Jul 11. doi: 10.1002/ijc.35092.
    

    >> Share

    
    June 2024
14. 
    Correction to "Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer".
    Int J Cancer. 2024 Jun 21. doi: 10.1002/ijc.35059.
    

    >> Share

    
    
15. ALHARBI M, Lai A, Godbole N, Guanzon D, et al
    Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering.
    Int J Cancer. 2024 Jun 7. doi: 10.1002/ijc.35055.
    

    >> Share

    
    May 2024
16. CHAO X, Kai Z, Wu H, Wang J, et al
    Fragmentomics features of ovarian cancer.
    Int J Cancer. 2024 May 20. doi: 10.1002/ijc.34981.
    

    >> Share

    
    
17. HUANG C, Bu H, Wang Y, Chu R, et al
    Association between coffee and tea consumption and ovarian cancer incidence: A prospective analysis in the PLCO dataset.
    Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34982.
    

    >> Share

    
    
18. TAGUCHI A, Kato K, Furusawa A, Hara K, et al
    Heterogeneous treatment effect of dose-dense paclitaxel plus carboplatin therapy for advanced ovarian cancer.
    Int J Cancer. 2024 May 7. doi: 10.1002/ijc.34996.
    

    >> Share

    
    
19. FROMHAGE G, Obermayr E, Bednarz-Knoll N, Van Gorp T, et al
    Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
    Int J Cancer. 2024 May 6. doi: 10.1002/ijc.34976.
    

    >> Share

    
    April 2024
20. OBERMAYR E, Mohr T, Schuster E, Braicu EI, et al
    Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
    Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34978.
    

    >> Share

    
    March 2024
21. DUUS AH, Hannibal CG, Baandrup L, Zheng G, et al
    Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study.
    Int J Cancer. 2024 Mar 26. doi: 10.1002/ijc.34936.
    

    >> Share

    
    
22. HOLY P, Hlavac V, Seborova K, Susova S, et al
    Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34908.
    

    >> Share

    
    February 2024
23. GIZAW M, Parkin DM, Stoter O, Bukirwa P, et al
    Ovarian cancer survival in sub-Saharan Africa by human development index and histological subtypes: A population-based registry study.
    Int J Cancer. 2024 Feb 10. doi: 10.1002/ijc.34877.
    

    >> Share

    
    January 2024
24. WANG X, Sun J, Liu Y, Lin Z, et al
    Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma.
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34844.
    

    >> Share

    
    October 2023
25. XIA D, Xu X, Du P
    Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34785.
    

    >> Share

    
    
26. KIM YN, Joung JG, Park E, Kim JW, et al
    Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34786.
    

    >> Share

    
    
27. HERZOG C, Jones A, Evans I, Reisel D, et al
    Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.
    Int J Cancer. 2023 Oct 20. doi: 10.1002/ijc.34757.
    

    >> Share

    
    August 2023
28. KIM YN, Joung JG, Park E, Kim JW, et al
    Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
    Int J Cancer. 2023 Aug 21. doi: 10.1002/ijc.34696.
    

    >> Share

    
    June 2023
29. FRANDSEN CLB, Svendsen PF, Nohr B, Viuff JH, et al
    Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: A nationwide population-based cohort study.
    Int J Cancer. 2023 Jun 26. doi: 10.1002/ijc.34574.
    

    >> Share

    
    May 2023
30. FORTNER RT, Trewin-Nybraten CB, Paulsen T, Langseth H, et al
    Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway.
    Int J Cancer. 2023 May 25. doi: 10.1002/ijc.34576.
    

    >> Share

    
    March 2023
31. SENKUS E, Delaloge S, Domchek SM, Conte P, et al
    Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial.
    Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34525.
    

    >> Share

    
    
32. SILVA R, Glennon K, Metoudi M, Moran B, et al
    Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34496.
    

    >> Share

    
    February 2023
33. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
    Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
    

    >> Share

    
    January 2023
34. HUANG RY, Huang KJ, Chen KC, Hsiao SM, et al
    Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
    Int J Cancer. 2023 Jan 11. doi: 10.1002/ijc.34428.
    

    >> Share

    
    December 2022
35. VELLE A, Pesenti C, Grassi T, Beltrame L, et al
    A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers.
    Int J Cancer. 2022 Dec 21. doi: 10.1002/ijc.34408.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share